IRWD on Nasdaq

Ironwood Pharmaceuticals

American pharmaceutical company

Ironwood Pharmaceuticals, Inc. is a publicly traded pharmaceutical company.3 From Wikipedia, CC BY-SA 4.0

Price unavailable

Last updated Oct 19, 2026.

Overview

1998Founded1

Compare with Evolus, Inc., RIGEL PHARMACEUTICALS INC or Xeris Biopharma Holdings, Inc., or pick any stock.

  • TickerIRWD on Nasdaq1
  • IndustryPharmaceutical Preparations1
  • HeadquartersCambridge1
  • Websitewww.ironwoodpharma.com
  • Legal formDelaware corporation1
  • Incorporated inDE5
  • Business address100 Summer Street, Suite 2300, Boston, Ma 021105
  • Filer categoryAccelerated filer, Smaller reporting company5
  • LEI549300PC8MR6QHH6P2964
  • StatusActive4
  • LEI statusLapsed (not renewed)4
  • Registered addressc/o The Corporation Trust Company, 19801 Wilmington, United States4
  • Registered withDivision of Corporations, Department of State, 28310754

See how the biggest companies compare on our leaderboards

Ironwood Pharmaceuticals, Inc. is a publicly traded pharmaceutical company. It was originally called Microbia, Inc.3

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

33.3%Operating margin6
8.1%Net margin6
-15.7%Revenue growth, 20256
$127.0MFree cash flow6

What sells

Revenue by product, business segment and region, as the company reports it to the SEC.

Products and services

Collaborative Arrangements brought in 100% of the revenue Ironwood Pharmaceuticals broke down this way in fiscal 2025.

  1. Collaborative Arrangements$296.2M6100%down 16% from 2024
  2. Collaborative arrangement, other agreements$87.0K60%down 88% from 2024
Products and services by year
Products and services20242025
Collaborative Arrangements$351.4M$296.2M
Collaborative arrangement, other agreements$734.0K$87.0K

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Research and development32¢$95.1M
  • Selling, general and admin28¢$82.3M
  • Other costs16¢$48.7M
  • Income tax16¢$46.0M
  • Profit8¢$24.0M

Out of $296.2M in revenue.6

Where each dollar of operating cash went, fiscal 2025

  • Capital spending0¢$34.0K
  • Kept or used elsewhere100¢$127.0M

Out of $127.0M of cash from operations.6

Financial statements

Revenue789106$296.2M in 2025−31% since 2019
0$200.0M$400.0M$600.0M2019: $428.4M$428.4M20192020: $389.5M$389.5M2020−9%2021: $413.8M$413.8M2021+6%2022: $410.6M$410.6M2022−1%2023: $442.7M$442.7M2023+8%2024: $351.4M$351.4M2024−21%2025: $296.2M$296.2M2025−16%
Operating income789106$98.5M in 2025−18% since 2019
-$1.0B-$500.0M0$500.0M2019: $120.1M$120.1M20192020: $142.9M$142.9M2020+19%2021: $232.3M$232.3M2021+62%2022: $250.3M$250.3M2022+8%2023: -$945.4M-$945.4M20232024: $93.1M$93.1M20242025: $98.5M$98.5M2025+6%
Net income789106$24.0M in 2025+12% since 2019
-$1.5B-$1.0B-$500.0M0$500.0M$1.0B2019: $21.5M$21.5M20192020: $106.2M$106.2M2020+394%2021: $528.4M$528.4M2021+398%2022: $175.1M$175.1M2022−67%2023: -$1.0B-$1.0B20232024: $880.0K$880.0K20242025: $24.0M$24.0M2025+2629%

Every line of the income statement as filed: the last 2 fiscal years (annual) or 8 quarters (quarterly), latest first.6

Period ending2025-12-312024-12-31
Total revenues$296.2M$351.4M
Research and development$95.1M$111.4M
Selling, general and administrative$82.3M$144.3M
Restructuring, net$20.3M$2.6M
Total costs and expenses$197.6M$258.3M
Income from operations$98.5M$93.1M
Interest expense and other financing costs-$32.7M-$33.0M
Interest and investment income$4.1M$4.5M
Other$193.0K$640.0K
Other income (expense), net-$28.5M-$27.9M
Income before income taxes$70.0M$65.2M
Income tax expense-$46.0M-$64.3M
Net income$24.0M$880.0K
Net income per share - basic (in dollars per share)$0.15$0.01
Net income per share - diluted (in dollars per share)$0.15$0.01
Weighted average shares used in computing net income per share - basic (in shares)161.8M shares159.1M shares
Weighted average shares used in computing net income per share - diluted (in shares)163.0M shares160.1M shares

Compare Ironwood Pharmaceuticals with another company

Leadership

Who has led Ironwood Pharmaceuticals, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Peter M. Hecht2010–2019
  2. Mark Mallon2019–2021
  3. Thomas A. McCourt2021–now

President

  1. Thomas A. McCourt2019–2021

Chief financial officer

  1. Thomas Graney2014–2017
  2. Gina Consylman2017–2021
  3. Sravan Kumar Emany2021–2024
  4. Gregory S. Martini2025–now

Chief operating officer

  1. William Huyett2017–2019
  2. Jason Rickard2020–2023
  3. Sravan Kumar Emany2024
200020052010201520202025
Board members and other officers (35)

Timeline

  1. Mar 30, 2021New chief executive Thomas A. McCourt becomes CEO14
  2. Apr 3, 2019New chief executive Mark Mallon becomes CEO15
  3. Feb 3, 2010Went public Listed on NASDAQ1
  4. Feb 2, 2010New chief executive Peter M. Hecht becomes CEO16
  5. 1998Founded Founded1

Filings

398 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 52 major events, 205 insider forms, 49 large holders, 72 other. The latest 20:

  1. Sep 23, 2026144 EDGAR
  2. Sep 17, 20264 EDGAR
  3. Aug 14, 2026SCHEDULE 13G/A EDGAR
  4. Aug 7, 2026SCHEDULE 13G EDGAR
  5. Aug 6, 202610-Q EDGAR
  6. Aug 6, 20268-K EDGAR
  7. Jul 28, 2026SCHEDULE 13G/A EDGAR
  8. Jul 22, 20264 EDGAR
  9. Jul 22, 20263 EDGAR
  10. Jul 9, 20264 EDGAR
  11. Jul 7, 2026144 EDGAR
  12. Jun 18, 20268-K EDGAR
  13. Jun 17, 20264 EDGAR
  14. Jun 17, 20264 EDGAR
  15. Jun 17, 20264 EDGAR
  16. Jun 17, 20264 EDGAR
  17. Jun 17, 20264 EDGAR
  18. Jun 17, 20264 EDGAR
  19. Jun 17, 20264 EDGAR
  20. Jun 16, 2026144 EDGAR

The 398 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

104 open-market trades by officers, directors and large owners since October 2021: 3 buys and 101 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Jul 7, 2026Silver RonaldPFO & PAOSale127,890$4.52$578.1KForm 4
Jun 16, 2026McHugh JulieDirectorSale21,571$3.73$80.5KForm 4
Mar 17, 2026DENNER ALEXANDER JDirectorSale6,730,800$3.05$20.5MForm 4
Feb 24, 2026Martini Gregory S.Chief Financial OfficerSale11,457$3.66$41.9KForm 4
Feb 24, 2026John MinardoChief Legal OfficerSale19,053$3.66$69.7KForm 4
Feb 24, 2026Shetzline MichaelSVP, CMO, Head-Res&DrugSale17,012$3.66$62.3KForm 4
Feb 24, 2026Gaskins Tammi LChief Commercial OfficerSale11,239$3.66$41.1KForm 4
Feb 24, 2026MCCOURT Thomas AChief Executive OfficerSale103,526$3.66$378.9KForm 4
Feb 24, 2026Silver RonaldPFO & PAOSale12,621$3.66$46.2KForm 4
Feb 23, 2026Martini Gregory S.Chief Financial OfficerSale10,487$3.81$40.0KForm 4
Feb 23, 2026John MinardoChief Legal OfficerSale17,439$3.81$66.4KForm 4
Feb 23, 2026Shetzline MichaelSVP, CMO, Head-Res&DrugSale15,570$3.81$59.3KForm 4
Feb 23, 2026Gaskins Tammi LChief Commercial OfficerSale10,287$3.81$39.2KForm 4
Feb 23, 2026MCCOURT Thomas AChief Executive OfficerSale94,757$3.81$361.0KForm 4
Feb 23, 2026Silver RonaldPFO & PAOSale11,552$3.81$44.0KForm 4
Jan 5, 2026Silver RonaldPFO & PAOSale35,416$4.60$162.9KForm 4
Nov 17, 2025Gaskins Tammi LChief Commercial OfficerSale6,016$3.32$20.0KForm 4
Aug 11, 2025Gaskins Tammi LChief Commercial OfficerSale1,316$0.84$1.1KForm 4
Aug 11, 2025John MinardoChief Legal OfficerSale7,754$0.84$6.5KForm 4
Aug 11, 2025Silver RonaldPFO & PAOSale2,846$0.84$2.4KForm 4

All 104 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
BlackRock, Inc.17,788,557$74.9M0.0%+4,425,627
Armistice Capital, LLC13,932,000$58.7M1.6%−1,096,000
Sarissa Capital Management LP9,188,635$38.7M21.7%No change
State Street Corp8,809,601$37.1M0.0%+1,352,657
Bank Of America Corp /de/8,683,803$36.6M0.0%+896
Renaissance Technologies LLC7,993,226$33.7M0.0%−67,847
Vanguard Capital Management LLC6,608,508$27.8M0.0%+511,054
Aqr Capital Management LLC6,465,921$27.2M0.0%−1,069,159
Vanguard Portfolio Management LLC5,513,355$23.2M0.0%−1,168,682
Geode Capital Management, LLC4,831,657$20.3M0.0%+288,135
Two Sigma Investments, LP4,556,089$19.2M0.0%−1,292,187
Marshall Wace, Llp4,290,093$18.1M0.0%−234,971
Jacobs Levy Equity Management, Inc4,065,964$17.1M0.1%+433,487
Goldman Sachs Group Inc3,313,808$14.0M0.0%+623,174
Charles Schwab Investment Management Inc3,302,242$13.9M0.0%−1,435,615
Federated Hermes, Inc.3,231,238$13.6M0.0%−117,568
Arrowstreet Capital, Limited Partnership3,017,089$12.7M0.0%−380,153
Dimensional Fund Advisors LP2,522,891$10.6M0.0%+440,836
Mackenzie Financial Corp2,367,493$10.0M0.0%+1,807,459
Morgan Stanley1,859,914$7.8M0.0%+1,035,095
Connor, Clark & Lunn Investment Management Ltd.1,811,714$7.6M0.0%−23,710
Northern Trust Corp1,373,974$5.8M0.0%+108,132
Hillsdale Investment Management Inc.1,250,428$5.3M0.1%+13,800
Wells Fargo & Company/mn1,206,198$5.1M0.0%+1,147,348
Deutsche Bank Ag\1,158,138$4.9M0.0%+33,149

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59
  60. 60
  61. 61
  62. 62
  63. 63
  64. 64
  65. 65
  66. 66
  67. 67
  68. 68
  69. 69
  70. 70